Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.

@article{Sandborn2011CertolizumabPF,
  title={Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.},
  author={William J Sandborn and Stefan Schreiber and Brian G Feagan and P. R. Rutgeerts and Ziad Younes and Ralph Bloomfield and Geoffroy Coteur and Juan Pablo Guzman and G D'Haens},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2011},
  volume={9 8},
  pages={
          670-678.e3
        }
}
BACKGROUND & AIMS Certolizumab pegol (CZP) is a pegylated-conjugated Fab' against tumor necrosis factor (TNF). Additional data are needed regarding the efficacy of induction therapy with CZP in active Crohn's disease (CD). METHODS A placebo-controlled trial evaluated the efficacy of CZP therapy in 439 adults with moderate to severe CD naive to anti-TNF therapy. Patients were randomized to receive CZP (400 mg subcutaneously) or placebo at weeks 0, 2, and 4. The primary end point was clinical… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 51 CITATIONS

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 6 Citations per year over the last 3 years

Similar Papers

Loading similar papers…